| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | ABT-888 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | XMD8-85 | GDSC1000 | pan-cancer | AAC | 0.023 | 0.6 |
| mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.6 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.7 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
| mRNA | Genentech Cpd 10 | GDSC1000 | pan-cancer | AAC | 0.014 | 0.7 |